Stratos Wealth Partners LTD. Has $512,000 Position in Moderna, Inc. (NASDAQ:MRNA)

Stratos Wealth Partners LTD. lowered its position in Moderna, Inc. (NASDAQ:MRNA) by 18.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,145 shares of the company’s stock after selling 1,126 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Moderna were worth $512,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in MRNA. RB Capital Management LLC increased its stake in shares of Moderna by 7.5% in the first quarter. RB Capital Management LLC now owns 2,267 shares of the company’s stock valued at $391,000 after buying an additional 158 shares during the period. Synovus Financial Corp boosted its holdings in shares of Moderna by 8.0% during the 1st quarter. Synovus Financial Corp now owns 4,049 shares of the company’s stock worth $704,000 after buying an additional 300 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Moderna by 5.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 987,478 shares of the company’s stock worth $170,121,000 after buying an additional 47,755 shares in the last quarter. Blair William & Co. IL lifted its holdings in shares of Moderna by 12.4% in the 1st quarter. Blair William & Co. IL now owns 15,611 shares of the company’s stock worth $2,689,000 after purchasing an additional 1,724 shares in the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of Moderna by 41.4% in the 1st quarter. Sei Investments Co. now owns 58,160 shares of the company’s stock worth $10,019,000 after purchasing an additional 17,031 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Down 1.7 %

MRNA stock opened at $105.14 on Friday. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $40.26 billion, a PE ratio of -8.47 and a beta of 1.62. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $163.24. The stock has a 50-day simple moving average of $99.86 and a two-hundred day simple moving average of $93.57.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. The business had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company’s quarterly revenue was down 44.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.61 EPS. On average, equities analysts predict that Moderna, Inc. will post -7.48 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the completion of the sale, the director now owns 2,101,931 shares in the company, valued at approximately $229,236,594.86. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, President Stephen Hoge sold 2,388 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00. Following the transaction, the director now directly owns 2,101,931 shares in the company, valued at $229,236,594.86. The disclosure for this sale can be found here. Insiders sold 94,954 shares of company stock valued at $9,966,476 in the last quarter. 15.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

MRNA has been the topic of several recent analyst reports. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a research note on Tuesday, January 2nd. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Canaccord Genuity Group raised their target price on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Thursday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $125.00 target price on shares of Moderna in a research report on Thursday, March 28th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.